Evidence map›Paper›PMID 33766652›Full record

ArticleNeurobiology of disease2021

Impairment of visual cortical plasticity by amyloid-beta species.

Christopher M William, Matthew A Stern, Xuewei Pei, Lubna Saqran, Margish Ramani, Matthew P Frosch, Bradley T Hyman

Open access · goldAbstract read
In one paragraph

Article in Neurobiology of disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Early detection of Alzheimer's disease using the MEMORIES mnemonic.Chronic diseases and translational medicine · 2025
    Review
  2. Amyloid Pathology Impairs Experience-Dependent Inhibitory Synaptic Plasticity.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Christopher M WilliamNew York University Grossman School of Medicine, Department of Pathology, 550 First Avenue, New York, NY 10016, United States. Electronic address: christopher.william@nyulangone.org.
Matthew A SternMassGeneral Institute for Neurodegenerative Disease, Neurology, Massachusetts General Hospital, 114 16th St., Charlestown, MA 02129, United States. Electronic address: matthew.a.stern@emory.edu.
Xuewei PeiNew York University Grossman School of Medicine, Department of Pathology, 550 First Avenue, New York, NY 10016, United States.
Lubna SaqranMassGeneral Institute for Neurodegenerative Disease, Neurology, Massachusetts General Hospital, 114 16th St., Charlestown, MA 02129, United States.
Margish RamaniNew York University Grossman School of Medicine, Department of Pathology, 550 First Avenue, New York, NY 10016, United States. Electronic address: margish.ramani@nyulangone.org.
Matthew P FroschNeuropathology Service, Massachusetts General Hospital, 114 16th St., Charlestown, MA 02129, United States; MassGeneral Institute for Neurodegenerative Disease, Neurology, Massachusetts General Hospital, 114 16th St., Charlestown, MA 02129, United States. Electronic address: mfrosch@mgh.harvard.edu.
Bradley T HymanMassGeneral Institute for Neurodegenerative Disease, Neurology, Massachusetts General Hospital, 114 16th St., Charlestown, MA 02129, United States. Electronic address: bhyman@mgh.harvard.edu.
MaineGeneral Medical Center · USNew York University · USMassachusetts General Hospital · US

Funding

THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
Research Education ComponentP30AG066512 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI THOMAS M WISNIEWSKI · 2020 to 2026
$28.4M
Synaptic Plasticity in Alzheimer Disease Mouse ModelsK08NS069811 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WILLIAM, CHRISTOPHER MAGED · 2010 to 2014
$921k
NIA NIH HHS P30 AG066512NIA NIH HHS P50 AG005134NINDS NIH HHS K08 NS069811
6 · The paper itself

Abstract

introductionA variety of transgenic and knock-in mice that express mutant alleles of Amyloid precursor protein (APP) have been used to model the effects of amyloid-beta (Aβ) on circuit function in Alzheimer's disease (AD); however phenotypes described in these mice may be affected by expression of mutant APP or proteolytic cleavage products independent of Aβ. In addition, the effects of mutant APP expression are attributed to elevated expression of the amyloidogenic, 42-amino acid-long species of Aβ (Aβ42) associated with amyloid plaque accumulation in AD, though elevated concentrations of Aβ40, an Aβ species produced with normal synaptic activity, may also affect neural function.

methodsTo explore the effects of elevated expression of Aβ on synaptic function in vivo, we assessed visual system plasticity in transgenic mice that express and secrete Aβ throughout the brain in the absence of APP overexpression. Transgenic mice that express either Aβ40 or Aβ42 were assayed for their ability to appropriately demonstrate ocular dominance plasticity following monocular deprivation.

resultsUsing two complementary approaches to measure the plastic response to monocular deprivation, we find that male and female mice that express either 40- or 42-amino acid-long Aβ species demonstrate a plasticity defect comparable to that elicited in transgenic mice that express mutant alleles of APP and Presenilin 1 (APP/PS1 mice).

conclusionsThese data support the hypothesis that mutant APP-driven plasticity impairment in mouse models of AD is mediated by production and accumulation of Aβ. Moreover, these findings suggest that soluble species of Aβ are capable of modulating synaptic plasticity, likely independent of any aggregation. These findings may have implications for the role of soluble species of Aβ in both development and disease settings.

Indexed as

Amyloid beta-PeptidesAnimalsDominance, OcularFemaleMaleMiceMice, TransgenicNeuronal PlasticityPeptide FragmentsVisual CortexAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)Peptide FragmentsAlzheimer's diseaseAmyloid-beta-40 (Aβ40)Amyloid precursor protein (APP)Aβ42Ocular dominance plasticitySynaptic plasticityVisual cortex

Identifiers

PMID33766652
PMCPMC8113107
OpenAlexW3136197155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.